Skip to main content

Table 1 Patients main characteristics at ICU admission

From: Impact of dexamethasone on the incidence of ventilator-associated pneumonia and blood stream infections in COVID-19 patients requiring invasive mechanical ventilation: a multicenter retrospective study

 

Overall

(n = 151)

DEXA+

(n = 84)

DEXA−

(n = 67)

Male, n (%)

120 (79)

65 (77)

55 (82)

Age, years ± SD

64 ± 12

66 ± 11

62 ± 13

SAPS 2, mean ± SD

42 ± 14

42 ± 13

42 ± 15

SOFA, mean ± SD

6 ± 4

5 ± 4

6 ± 3

Comorbidities, n (%)

   

 Hypertension

73 (48)

43 (51)

30 (45)

 Diabetes mellitus

55 (36)

34 (40)

21 (31)

 Obesity

44 (29)

24 (29)

20 (30)

 Smoker

37 (25)

18 (21)

19 (28)

 Chronic heart failure

27 (18)

12 (14)

15 (22)

 Chronic respiratory failure

20 (13)

11 (13)

9 (13)

 History of neoplasm

18 (12)

12(14)

6 (9)

 Immunosuppression

11 (7)

6 (7)

5 (7)

 Chronic renal failure

9 (6)

6 (7)

3 (4)

Antiviral agents, n (%)

22 (15)

0

22 (33)

 Lopinavir–ritonavir

21 (14)

0

21 (31)

 Remdesivir

1 (1)

0

1 (2)

Hydroxychloroquine, n (%)

37 (25)

2 (2)

35 (52)

Antimicrobial treatment at ICU admission, n (%)

110 (73)

52 (62)

58 (87)

Documented co-infection, n (%)

16 (11)

6 (7)

9 (13)

Time from hospital admission to ICU admission, days, median (IQR)

0 (0–2)

0 (0–2)

0 (0–2)

Invasive MV at ICU admission, n (%)

70 (46)

30 (36)

40 (60)

Time to intubation, days, median (IQR)

1 (0–2)

1 (0–4)

0 (0–1)

Time from dexamethasone to intubation, days, median (IQR)

–

1 (0–4)

–

ECMO, n (%)

29 (19)

15 (18)

14 (21)

Hydrocortisone for septic shock, n (%)

27 (18)

11 (13)

16 (24)

  1. Data are presented as median and interquartile range or mean ± standard deviation or absolute value and percentage